MTOR and neuroblastoma: The finding of synergism in different cancer types with activating NRAS mutations is not surprising, because NRAS mutant melanoma, lung cancer and neuroblastoma all seem to depend on NRAS downstream signaling through MAPK and PI3K/AKT/mTOR [3,10].